BrainStorm Cell Therapeutics Inc. announced that it has entered into a collaborative agreement with Hadassah Medical Center in Jerusalem, Israel, to conduct the planned multi dose Phase 2 trial with NurOwn in Amyotrophic Lateral Sclerosis (ALS). This Phase 2 multi dose study will be BrainStorm's third clinical trial conducted at Hadassah and is designed to provide guidance in preparing a Phase 3 program for NurOwn stem cell based therapy in ALS. The trial is expected to enroll up to 24 patients who will receive three consecutive stem cell transplantations in order to explore the safety and efficacy of a multi dose treatment.

Commencement of the trial is subject to approval by both Hadassah's Helsinki Committee and the Israeli Ministry of Health.